Technology Offerings

Innovative ATGL Inhibitors Target Diabetes II and Cachexia

The University offers a new technology addressing at least the two markets of tumour-induced cachexia and diabetes type II. Cancer has become a constantly increasing problem and thus about 1 % of all people in highly developed countries are hit by cachexia, leading to approximately 9 million patients for Europe, Japan and the US. Furthermore, diabetes type II is one of the major lifestyle diseases in the modern world.

Further information: PDF

Wissenstransferzentrum Süd (WTZ Süd)
Phone: +43(0)316-873 6925

Contact
Moritz Theisen

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

Comments (0)

Write a comment